Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$6.87 - $10.96 $27,005 - $43,083
-3,931 Reduced 9.14%
39,097 $288,000
Q3 2022

Nov 14, 2022

SELL
$9.44 - $11.76 $80,872 - $100,747
-8,567 Reduced 16.6%
43,028 $425,000
Q2 2022

Aug 15, 2022

BUY
$9.31 - $11.84 $26,002 - $33,069
2,793 Added 5.72%
51,595 $563,000
Q1 2022

May 16, 2022

BUY
$10.84 - $16.55 $71,348 - $108,932
6,582 Added 15.59%
48,802 $552,000
Q4 2021

Feb 14, 2022

SELL
$15.69 - $21.14 $184,498 - $248,585
-11,759 Reduced 21.78%
42,220 $662,000
Q3 2021

Nov 15, 2021

BUY
$15.35 - $21.27 $486,472 - $674,088
31,692 Added 142.2%
53,979 $925,000
Q2 2021

Aug 13, 2021

BUY
$15.71 - $21.51 $350,128 - $479,393
22,287 New
22,287 $479,000

Others Institutions Holding VNDA

About Vanda Pharmaceuticals Inc.


  • Ticker VNDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,561,500
  • Market Cap $269M
  • Description
  • Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...
More about VNDA
Track This Portfolio

Track Guggenheim Capital LLC Portfolio

Follow Guggenheim Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.